tiprankstipranks
Trending News
More News >
Fiji Kava Limited (AU:CCO)
ASX:CCO
Australian Market

Fiji Kava Limited (CCO) AI Stock Analysis

Compare
10 Followers

Top Page

AU

Fiji Kava Limited

(Sydney:CCO)

Rating:36Underperform
Price Target:
The overall stock score reflects significant revenue growth overshadowed by critical financial weaknesses, including negative equity and ongoing losses. Technical analysis is inconclusive due to insufficient data, and valuation metrics highlight the company's current financial struggles.

Fiji Kava Limited (CCO) vs. iShares MSCI Australia ETF (EWA)

Fiji Kava Limited Business Overview & Revenue Model

Company DescriptionThe Calmer Co International Limited operates as a medicinal kava health and wellness company in Australia, New Zealand, Fiji, and the United States. It produces and sells noble kava extract capsules, and powder mixes under the Fiji Kava and Taki Mai brand names. The company also sells its products through fijikava.com. The company was formerly known as Fiji Kava Limited and changed its name to The Calmer Co International Limited in April 2023. The Calmer Co International Limited was incorporated in 2014 and is based in West End, Australia.
How the Company Makes MoneyFiji Kava Limited generates revenue primarily through the sale of its kava-based products. The company's key revenue streams include direct sales through its online platform and distribution partnerships with retail stores and health outlets. By establishing strategic partnerships with distributors and retailers, Fiji Kava Limited is able to reach a wider consumer base, enhancing its market presence and revenue potential. The company may also engage in wholesale agreements, allowing it to supply kava extracts to other businesses in the health and wellness industry. Additionally, Fiji Kava Limited's focus on product innovation and marketing helps drive consumer awareness and demand, further contributing to its revenue growth.

Fiji Kava Limited Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
Breakdown
Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
4.26M1.78M2.08M1.16M758.87K
Gross Profit
2.05M-1.40M665.97K404.43K184.33K
EBIT
-1.88M-4.30M-5.42M-3.28M-3.69M
EBITDA
-3.35M-4.86M-5.72M-3.19M-3.56M
Net Income Common Stockholders
-3.73M-5.24M-5.46M-3.39M-3.81M
Balance SheetCash, Cash Equivalents and Short-Term Investments
1.10M462.15K799.22K1.18M1.43M
Total Assets
4.33M3.24M4.79M3.60M2.95M
Total Debt
2.21M2.35M1.08M125.00K750.38K
Net Debt
1.11M1.92M278.21K-1.06M-679.85K
Total Liabilities
4.80M3.32M2.51M694.78K1.56M
Stockholders Equity
-466.84K-87.53K2.28M2.91M1.38M
Cash FlowFree Cash Flow
-2.19M-3.82M-7.10M-4.40M-3.67M
Operating Cash Flow
-2.08M-3.80M-6.14M-4.14M-3.54M
Investing Cash Flow
-116.97K-21.08K-964.94K-259.37K-135.57K
Financing Cash Flow
2.83M3.47M6.03M4.16M2.79M

Fiji Kava Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
$8.88B15.034.75%203.74%3.58%-2.49%
AUCCO
36
Underperform
AU$9.03M-548.03%192.34%68.06%
$25.71M-75.39%
$7.80M-177.18%
AUVLS
73
Outperform
AU$110.36M12.6718.35%5.00%7.21%-4.07%
AUBOT
53
Neutral
AU$647.09M-56.99%10.76%-195.89%
AUEVE
34
Underperform
AU$4.75M-105.17%-3.82%51.47%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:CCO
Fiji Kava Limited
0.01
0.00
0.00%
CYYNF
Cynata Therapeutics Limited
0.12
<0.01
9.09%
TNYYF
Tinybeans Group
0.02
>-0.01
-33.33%
AU:VLS
Vita Life Sciences Limited
2.00
-0.16
-7.41%
AU:EVE
EVE Health Group Limited
0.04
0.01
33.33%
AU:BOT
Botanix Pharmaceuticals Limited
0.34
0.06
21.43%

Fiji Kava Limited Corporate Events

The Calmer Co. Issues New Shares Amid Compliance Assurance
May 29, 2025

The Calmer Co International Limited has issued 37,500 fully paid ordinary shares following the exercise of options, as per the Corporations Act 2001. This move, authorized by the company’s Board of Directors, reflects compliance with relevant legal provisions and indicates no excluded information is required to be disclosed. This issuance could impact the company’s financial structure and stakeholder interests.

The Calmer Co. Expands Kava Product Distribution in Coles Supermarkets
May 25, 2025

The Calmer Co. International Limited has announced a significant expansion in the distribution of its flagship kava products, Taki Mai Kava-shot and FijiKava Instant Kava, in Coles Supermarkets across Australia. The Taki Mai Kava-shot is now available in 797 stores, and the FijiKava Instant Kava is in 801 stores, reflecting a 59% and 170% increase in store coverage, respectively. This expansion is driven by the growing consumer demand for natural wellness products that offer functional alternatives to alcohol. The company views this growth as a validation of its strategy and leadership in the kava market, further strengthening its brand presence in the Australian retail channel.

Director’s Interest Change at The Calmer Co International Limited
May 20, 2025

The Calmer Co International Limited has announced a change in the director’s interest notice, specifically regarding John Homewood. Homewood Venture Capital Pty Ltd and Ace Property Holdings Pty Ltd, both associated with Mr. Homewood, have increased their holdings in the company through the acquisition of additional fully paid ordinary shares and options. This change reflects an allocation of shares and options pursuant to a rights offer, potentially impacting the company’s market positioning by increasing insider holdings.

The Calmer Co International Limited Announces New Securities Quotation
May 19, 2025

The Calmer Co International Limited has announced the quotation of new securities on the Australian Securities Exchange (ASX). The company will be quoting 75,666,667 ordinary fully paid shares and 37,833,335 options expiring on June 30, 2026. This move is part of previously announced transactions and may impact the company’s market presence by potentially increasing liquidity and investor interest.

The Calmer Co. Completes $1M Rights Issue to Fuel Expansion
May 16, 2025

The Calmer Co. International Limited has successfully completed its renounceable rights issue, raising $1,000,713 before costs. This capital will be allocated towards capital expenditure, inventory expansion, marketing, brand promotion, and general working capital. The company’s directors and management have shown strong commitment by participating in the rights issue, reflecting confidence in the company’s future. The issuance of new shares and options is scheduled for May 16, 2025, with Mahe Capital Pty Ltd acting as the lead manager and underwriter.

The Calmer Co. Sees 104% Growth in USA Amazon Sales
May 7, 2025

The Calmer Co. International Limited reported a significant 104% year-on-year increase in its USA Amazon sales for April 2025, reaching AUD$203,000. This growth is attributed to the strong performance of its Taki Mai traditional kava brand, which accounted for 24% of the sales, and a notable rise in subscription sales, making up 28% of the total sales volume. The company is strategically expanding its presence in the U.S. market by focusing on both its instant kava brand, Fiji Kava, and its heritage brand, Taki Mai, to capture different market segments. This expansion is part of a broader strategy to launch new products and invest in R&D for long-term success.

The Calmer Co. Expands US Market Reach with Leilo Partnership
May 7, 2025

The Calmer Co. International Limited has signed a non-binding Memorandum of Understanding with Leilo, a leading US functional beverage company, to supply high-grade noble kava powders from the South Pacific to US kava bars. This partnership aims to expand The Calmer Co.’s presence in the North American market, leveraging its expertise in kava supply and supporting the growing demand for non-alcoholic beverages. The collaboration is expected to enhance the company’s market positioning and provide a stable supply chain for Leilo’s kava bar partners, potentially leading to a formal long-term supply agreement.

Fiji Kava Positioned for Growth Amidst Expanding Kava Market
May 2, 2025

The global kava root extract market is projected to grow significantly, reaching USD 5.6 billion by 2033, driven by the food and beverage industry’s growth, increased use in cosmetics and personal care, and extensive R&D activities. This growth presents opportunities for Fiji Kava Limited to enhance its market positioning and expand its operations, benefiting stakeholders by tapping into the rising demand for natural relaxation products.

The Calmer Co. Announces $2.2 Million Entitlement Offer
Apr 23, 2025

The Calmer Co. International Limited has announced a pro rata renounceable entitlement offer to raise approximately $2.2 million. Eligible shareholders can subscribe for two new shares for every seven existing shares held, with the offer including a free attaching option. This capital raising initiative is aimed at strengthening the company’s financial position and potentially expanding its market presence.

The Calmer Co. Expands Financial Base with New Share Issuance
Apr 23, 2025

The Calmer Co. International Limited has issued 123,873,702 fully paid ordinary shares along with the same number of attaching CCOOA options. This issuance was done without disclosure to investors under Part 6D.2 of the Corporations Act 2001, and the company confirms compliance with relevant provisions of the Act. This strategic move is expected to enhance the company’s financial standing and operational capabilities, potentially impacting its market position and stakeholder interests positively.

The Calmer Co International Limited Announces New Securities Quotation
Apr 23, 2025

The Calmer Co International Limited has announced a new application for the quotation of securities on the Australian Securities Exchange (ASX). The company is set to quote 1,666,666 options with an expiration date of June 30, 2026, as part of previously announced transactions. This move is part of the company’s strategic efforts to enhance its market presence and provide more investment opportunities for stakeholders.

The Calmer Co International Limited Announces New Securities Quotation
Apr 23, 2025

The Calmer Co International Limited has announced the application for quotation of 1,666,666 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code CCO. This move signifies a strategic step in enhancing the company’s market presence and potentially increasing its shareholder base, reflecting a positive outlook for future growth and stakeholder engagement.

The Calmer Co International Limited Announces New Securities Quotation
Apr 17, 2025

The Calmer Co International Limited has announced a new application for the quotation of securities on the Australian Securities Exchange (ASX). This involves the listing of 122,207,036 options expiring on June 30, 2026, which were part of a previously announced transaction. This move is likely to impact the company’s market presence by increasing the liquidity of its securities and potentially attracting more investors.

The Calmer Co International Limited Announces New Securities Quotation
Apr 17, 2025

The Calmer Co International Limited has announced a new issuance of 122,207,036 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX) under the code CCO. This move is part of the company’s strategic efforts to enhance its market presence and provide liquidity to its shareholders, potentially impacting its operational dynamics and positioning within the industry.

The Calmer Co. and Fiji Rugby Union Launch Co-Branded Kava Products
Apr 17, 2025

The Calmer Co. International Limited has expanded its partnership with the Fiji Rugby Union by launching a new range of co-branded kava products, including instant kava powder and cold-pressed kava shots infused with dehydrated coconut water powder. This launch is significant for The Calmer Co. as it strengthens its position as the exclusive kava supplier to Fiji Rugby, highlighting the cultural and nutritional importance of coconuts to the Fijian people and rugby community. The products will be available in tourist retail outlets across Fiji and on Amazon USA, with a 10% royalty on sales paid to channel partners.

The Calmer Co. Initiates Rights Trading on ASX
Apr 17, 2025

The Calmer Co. International Limited announced the commencement of trading for the rights to its Renounceable Rights Issue under the ASX code CCOR. This development marks a significant step in the company’s financial strategy, potentially enhancing its market presence and providing stakeholders with new investment opportunities.

The Calmer Co International Launches $2.2 Million Entitlement Offer
Apr 14, 2025

The Calmer Co International Limited has announced a renounceable pro-rata entitlement offer to raise approximately $2.2 million by issuing up to 729,677,511 new shares. The offer is underwritten to $500,000 by Mahe Capital Pty Ltd and includes a Top Up Offer for eligible shareholders to subscribe for additional shares. This initiative aims to enhance the company’s capital structure and provide financial flexibility, potentially impacting its market positioning and shareholder value.

The Calmer Co International Limited Announces Proposed Securities Issue
Apr 14, 2025

The Calmer Co International Limited has announced a proposed issue of securities, including a standard pro rata issue of 729,677,511 ordinary fully paid shares and 364,838,756 options expiring on 30 June 2026. Additionally, a placement or other type of issue will see the issuance of 44,000,000 options. The announcement outlines key dates, including the ex-date on 17 April 2025, the record date on 22 April 2025, the offer closing date on 9 May 2025, and the issue date on 16 May 2025. This move is part of the company’s strategy to raise capital and potentially enhance its market position.

Calmer Co International Announces $2.2 Million Entitlement Offer
Apr 14, 2025

The Calmer Co International Ltd, a company listed on the ASX, has announced a renounceable entitlement offer to raise up to $2.2 million. This offer allows eligible shareholders to subscribe for two new shares for every seven existing shares at a price of $0.003 per share, which is a 50% discount to the last traded price. Additionally, shareholders will receive one free option for every two new shares, with an exercise price of $0.006 and an expiration date of June 30, 2026. The funds raised will be used to expand inventory, upgrade manufacturing equipment, and support marketing activities in Australia and the USA, as well as for new product launches and general working capital.

The Calmer Co International Limited Initiates Trading Halt for Capital Raising Announcement
Apr 14, 2025

The Calmer Co International Limited, listed on the Australian Securities Exchange under the code CCO, has requested a trading halt for its securities. This halt is pending an announcement related to a proposed capital raising, which is expected to be disclosed before the opening of trading on April 16, 2025. The company believes this halt is necessary to prevent uninformed trading and has been approved by the Board of Directors.

The Calmer Co. Expands Market Presence with New Share and Option Issuance
Mar 26, 2025

The Calmer Co. International Limited has issued a total of 3,801,004 fully paid ordinary shares and 3,324,163 CCOOA options as part of its recent financial activities, targeting professional investors. This strategic move is expected to enhance the company’s market presence and operational capabilities, potentially impacting its industry positioning favorably.

The Calmer Co International Limited Announces New Securities Quotation
Mar 26, 2025

The Calmer Co International Limited has announced a new application for the quotation of securities on the Australian Securities Exchange (ASX). The company is issuing 955,683 ordinary fully paid shares and 477,842 options expiring on June 30, 2026, to existing professional investors. This move is expected to enhance the company’s financial position and potentially strengthen its market presence.

The Calmer Co. Appoints New Chief Commercial Officer Amidst Global Kava Market Growth
Mar 23, 2025

The Calmer Co. International Limited has appointed Matthew Kowal as its new Chief Commercial Officer. Kowal, who brings over 20 years of experience in the beverage industry, will be responsible for overseeing sales, marketing, and strategic partnerships to drive growth initiatives both locally and internationally. His appointment comes at a time when the global kava market is experiencing significant growth, with sales expected to rise by over 14% annually. Kowal’s expertise in scaling beverage brands and executing market entry strategies is expected to play a crucial role in The Calmer Co.’s expansion efforts and its aim to make premium quality kava accessible worldwide.

The Calmer Co International Limited Announces New Securities Quotation
Mar 23, 2025

The Calmer Co International Limited has announced a new application for the quotation of securities on the Australian Securities Exchange (ASX). The announcement details the issuance of 2,846,321 options expiring on June 30, 2026, which are part of previously announced transactions. This move is likely to have implications for the company’s market operations and could influence its positioning within the industry.

The Calmer Co International Limited Issues New Securities
Mar 23, 2025

The Calmer Co International Limited, listed under the ASX code CCO, has announced a new issuance of 2,846,321 ordinary fully paid securities, which were quoted on March 21, 2025. This move indicates the company’s strategic efforts to potentially enhance its market position and provide additional value to its stakeholders.

The Calmer Co. Expands E-Commerce Strategy with New Leadership and Platform Transition
Mar 12, 2025

The Calmer Co. International Limited has appointed Andy Burger, a former senior buyer at Amazon, as the Head of E-Commerce to spearhead its direct-to-consumer expansion and transition to the Acuity e-commerce platform. This strategic move aims to optimize product visibility, improve customer engagement, and accelerate revenue growth across major online marketplaces. The transition to Acuity aligns with the company’s digital-first strategy, leveraging advanced AI-driven analytics and automation to enhance operational efficiency and support global expansion. The company is also on track to expand its product line with new kava-based offerings, capitalizing on the growing popularity of kava in the global market.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.